Charles Schwab Investment Management Inc Incyte Corp Transaction History

Charles Schwab Investment Management Inc

$519 Billion
Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Incyte Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,245,051 shares of INCY stock, worth $82 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,245,051

Previous 1,324,959 6.03%

Holding current value

$82 Million

Previous $75.5 Million 0.01%

% of portfolio

0.01%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$51.18 - $63.75 $4.09 Million - $5.09 Million	-79,908 Reduced 6.03%	1,245,051 $75.5 Million
Q1 2024 May 08, 2024	SELL	$56.55 - $66.59 $104,900 - $123,524	-1,855 Reduced 0.14%	1,324,959 $75.5 Million
Q4 2023 Feb 06, 2024	BUY	$52.16 - $64.19 $5.09 Million - $6.27 Million	97,614 Added 7.94%	1,326,814 $83.3 Million
Q3 2023 Nov 08, 2023	BUY	$57.77 - $65.93 $2.04 Million - $2.32 Million	35,240 Added 2.95%	1,229,200 $71 Million
Q2 2023 Aug 09, 2023	BUY	$60.95 - $75.51 $2.27 Million - $2.81 Million	37,252 Added 3.22%	1,193,960 $74.3 Million
Q1 2023 May 11, 2023	BUY	$70.23 - $86.01 $3.63 Million - $4.45 Million	51,693 Added 4.68%	1,156,708 $83.6 Million
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $1.73 Million - $2.16 Million	25,678 Added 2.38%	1,105,015 $88.8 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $236,990 - $296,721	3,581 Added 0.33%	1,079,337 $71.9 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $1.88 Million - $2.37 Million	-28,449 Reduced 2.58%	1,075,756 $81.7 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $3.09 Million - $3.73 Million	46,823 Added 4.43%	1,104,205 $87.7 Million
Q4 2021 Feb 11, 2022	BUY	$63.34 - $74.11 $4.1 Million - $4.8 Million	64,720 Added 6.52%	1,057,382 $77.6 Million
Q3 2021 Nov 16, 2021	BUY	$68.67 - $84.02 $4.49 Million - $5.49 Million	65,393 Added 7.05%	992,662 $68.3 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $2.74 Million - $3 Million	34,274 Added 3.84%	927,269 $78 Million
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $2.53 Million - $3.35 Million	-33,332 Reduced 3.6%	892,995 $72.6 Million
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $303,501 - $367,254	3,759 Added 0.41%	926,327 $80.6 Million
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $1.46 Million - $1.88 Million	17,142 Added 1.89%	922,568 $82.8 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $2.86 Million - $4.2 Million	-38,600 Reduced 4.09%	905,426 $94.1 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $1.87 Million - $2.55 Million	-29,634 Reduced 3.04%	944,026 $69.1 Million
Q4 2019 Feb 07, 2020	BUY	$73.04 - $95.72 $2.1 Million - $2.76 Million	28,795 Added 3.05%	973,660 $85 Million
Q3 2019 Nov 08, 2019	BUY	$72.82 - $86.52 $6.55 Million - $7.78 Million	89,927 Added 10.52%	944,865 $70.1 Million
Q2 2019 Aug 09, 2019	BUY	$73.52 - $88.7 $2.33 Million - $2.81 Million	31,680 Added 3.85%	854,938 $72.6 Million
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $10.1 Million - $14 Million	158,453 Added 23.83%	823,258 $70.8 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $1.2 Million - $1.43 Million	20,446 Added 3.17%	664,805 $42.3 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $664,306 - $798,566	10,758 Added 1.7%	644,359 $44.5 Million
Q2 2018 Aug 08, 2018	BUY	$60.85 - $83.98 $2.3 Million - $3.18 Million	37,841 Added 6.35%	633,601 $42.5 Million
Q1 2018 May 07, 2018	BUY	$83.06 - $100.98 $1.29 Million - $1.56 Million	15,493 Added 2.67%	595,760 $49.6 Million
Q4 2017 Jan 17, 2018	BUY	$93.56 - $116.6 $3.35 Million - $4.18 Million	35,815 Added 6.58%	580,267 $55 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $59.4 Million - $75.3 Million	544,452	544,452 $63.6 Million

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

766K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $14.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Incyte Corp Transaction History